company background image
SUPN logo

Supernus Pharmaceuticals NasdaqGM:SUPN Stock Report

Last Price

US$30.25

Market Cap

US$1.7b

7D

5.7%

1Y

-1.2%

Updated

21 Jul, 2024

Data

Company Financials +

Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Stock Report

Market Cap: US$1.7b

SUPN Stock Overview

A biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

SUPN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Supernus Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Supernus Pharmaceuticals
Historical stock prices
Current Share PriceUS$30.25
52 Week HighUS$35.44
52 Week LowUS$21.99
Beta0.91
11 Month Change11.87%
3 Month Change1.82%
1 Year Change-1.18%
33 Year Change10.93%
5 Year Change-6.72%
Change since IPO463.31%

Recent News & Updates

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Recent updates

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02
Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Nov 30
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Oct 19
Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?

Aug 31
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?

Supernus: Well Prepared For Upcoming Challenges

Aug 26

Shareholder Returns

SUPNUS PharmaceuticalsUS Market
7D5.7%-3.3%-1.8%
1Y-1.2%16.8%19.4%

Return vs Industry: SUPN underperformed the US Pharmaceuticals industry which returned 16.6% over the past year.

Return vs Market: SUPN underperformed the US Market which returned 19.4% over the past year.

Price Volatility

Is SUPN's price volatile compared to industry and market?
SUPN volatility
SUPN Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement5.9%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

Stable Share Price: SUPN has not had significant price volatility in the past 3 months.

Volatility Over Time: SUPN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005652Jack Khattarwww.supernus.com

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.

Supernus Pharmaceuticals, Inc. Fundamentals Summary

How do Supernus Pharmaceuticals's earnings and revenue compare to its market cap?
SUPN fundamental statistics
Market capUS$1.66b
Earnings (TTM)-US$15.51m
Revenue (TTM)US$597.40m

2.8x

P/S Ratio

-107.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SUPN income statement (TTM)
RevenueUS$597.40m
Cost of RevenueUS$76.63m
Gross ProfitUS$520.77m
Other ExpensesUS$536.28m
Earnings-US$15.51m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.28
Gross Margin87.17%
Net Profit Margin-2.60%
Debt/Equity Ratio0%

How did SUPN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.